JP2016503425A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016503425A5 JP2016503425A5 JP2015543121A JP2015543121A JP2016503425A5 JP 2016503425 A5 JP2016503425 A5 JP 2016503425A5 JP 2015543121 A JP2015543121 A JP 2015543121A JP 2015543121 A JP2015543121 A JP 2015543121A JP 2016503425 A5 JP2016503425 A5 JP 2016503425A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- composition
- cell
- fusion protein
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 38
- 229920001184 polypeptide Polymers 0.000 claims description 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 34
- 108020001507 fusion proteins Proteins 0.000 claims description 25
- 102000037865 fusion proteins Human genes 0.000 claims description 25
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 16
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 230000001404 mediated effect Effects 0.000 claims description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims description 6
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 230000002601 intratumoral effect Effects 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 230000006052 T cell proliferation Effects 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 239000004475 Arginine Substances 0.000 claims description 4
- 108091008874 T cell receptors Proteins 0.000 claims description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 4
- 210000000447 Th1 cell Anatomy 0.000 claims description 4
- 210000000068 Th17 cell Anatomy 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 230000001363 autoimmune Effects 0.000 claims description 4
- 230000024245 cell differentiation Effects 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 229920000724 poly(L-arginine) polymer Polymers 0.000 claims description 4
- 108010011110 polyarginine Proteins 0.000 claims description 4
- 230000000638 stimulation Effects 0.000 claims description 4
- 102100031150 Growth arrest and DNA damage-inducible protein GADD45 alpha Human genes 0.000 claims description 2
- 101001066158 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 alpha Proteins 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 230000005747 tumor angiogenesis Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 description 3
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261728368P | 2012-11-20 | 2012-11-20 | |
| US61/728,368 | 2012-11-20 | ||
| US201361774066P | 2013-03-07 | 2013-03-07 | |
| US61/774,066 | 2013-03-07 | ||
| PCT/US2013/070813 WO2014081728A1 (en) | 2012-11-20 | 2013-11-19 | Inhibitors of the t cell-specific alternative p38 activation pathway and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016503425A JP2016503425A (ja) | 2016-02-04 |
| JP2016503425A5 true JP2016503425A5 (https=) | 2016-11-10 |
Family
ID=50776497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015543121A Pending JP2016503425A (ja) | 2012-11-20 | 2013-11-19 | Ｔ細胞特異的代替的ｐ３８活性化経路の阻害剤および使用法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9359418B2 (https=) |
| EP (1) | EP2922865A4 (https=) |
| JP (1) | JP2016503425A (https=) |
| AU (1) | AU2013348112A1 (https=) |
| CA (1) | CA2891425A1 (https=) |
| WO (1) | WO2014081728A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111206098B (zh) * | 2020-02-10 | 2023-02-21 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | p38γ在制备胰腺癌预后诊断试剂中的应用 |
| CN119236082A (zh) * | 2024-10-16 | 2025-01-03 | 遵义医科大学附属医院 | Mapk4激动剂在制备类风湿性关节炎药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6613318B1 (en) * | 1999-03-25 | 2003-09-02 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for identifying inhibitors of GADD45 polypeptide activity, and inhibitors of such activity |
| US7354898B2 (en) * | 2001-10-02 | 2008-04-08 | University Of Chicago | Identification of novel factors that block programmed cell death or apoptosis by targeting JNK |
| AU2004203373A1 (en) | 2003-07-25 | 2005-02-10 | University Of Chicago | Identification of novel factors that block programmed cell death or apoptosis by targeting JNK |
| WO2005077983A2 (en) * | 2004-02-05 | 2005-08-25 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Modulating p38 kinase activity |
| US20100104536A1 (en) * | 2007-03-20 | 2010-04-29 | Indravadan Ambalal Modi | P38 inhibitors |
-
2013
- 2013-11-19 EP EP13857490.0A patent/EP2922865A4/en not_active Withdrawn
- 2013-11-19 US US14/443,278 patent/US9359418B2/en not_active Expired - Fee Related
- 2013-11-19 WO PCT/US2013/070813 patent/WO2014081728A1/en not_active Ceased
- 2013-11-19 AU AU2013348112A patent/AU2013348112A1/en not_active Abandoned
- 2013-11-19 CA CA2891425A patent/CA2891425A1/en not_active Abandoned
- 2013-11-19 JP JP2015543121A patent/JP2016503425A/ja active Pending